ARVN: Four clinical programs approach data catalysts, led by BCL6 and SBMA
Arvinas, Inc. (ARVN) has four clinical programs with data catalysts expected over the next 12 months. These include near-term BCL6 data and healthy-volunteer results for SBMA in the first half of next year. The company's ARV-393 compound showed a 44% overall response rate in nine evaluable T-cell lymphoma patients.
More than 3 million Arvinas (ARVN) shares make up D. E. Shaw's reported ownership position.
D. E. Shaw & Co., L.P. and David E. Shaw have reported beneficial ownership of 3,208,075 shares, or 4.9%, of Arvinas, Inc. (ARVN) as of September 30, 2026. This amended ownership report indicates shared voting power over 3,193,730 shares and shared dispositive power over the full 3,208,075 shares. David E. Shaw disclaims direct beneficial ownership.
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas (Nasdaq: ARVN) announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026, at 9:00 a.m. GMT/4:00 a.m. EST. A live audio webcast of the presentation will be available on the Investors and Media section of the company's website. Arvinas is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation, with several investigational drugs in clinical development.
Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded Arvinas (NASDAQ:ARVN) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains "Moderate Buy" with a target price of $15.18. The company's recent quarterly earnings reported a beat on EPS at -$0.82 but significantly missed revenue expectations at $0.50 million, a 98.8% year-over-year decrease. Despite the downgrade, shares were up 2.4% on the day, opening at $6.92.
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN) announced its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is a clinical-stage biotechnology firm focused on targeted protein degradation to develop new drugs. A live audio webcast of the presentation will be available for interested parties.
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas, Inc. announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company, a clinical-stage biotechnology firm, specializes in developing drugs based on targeted protein degradation using its PROTAC platform. Arvinas is currently advancing several investigational drugs for various debilitating diseases.
A 232-share tax sale at Arvinas (ARVN) was automatic, not discretionary.
Arvinas, Inc.'s VP and Chief Accounting Officer, David K. Loomis, automatically sold 232 shares of common stock at $6.3594 per share on November 9, 2026. This non-discretionary sale was executed to cover tax withholding obligations related to the vesting of 25% of his restricted stock units, as per a Rule 10b5-1 plan and durable sale instruction. Following the transaction, Loomis directly held 39,961 shares.
Form 4 Arvinas Inc: David K. Loomis (VP, Chief Accounting Officer) For: 9 November By Investing.com
This article reports on a Form 4 filing for Arvinas Inc., specifically detailing activity by David K. Loomis, the VP and Chief Accounting Officer. The filing is dated for November 9th. The article is a brief announcement without further details on the nature of the transaction.
Form 4 Arvinas Inc: David K. Loomis (VP, Chief Accounting Officer) For: 9 November
This article reports that David K. Loomis, VP and Chief Accounting Officer of Arvinas Inc., filed a Form 4 for November 9th. The Form 4 is a document filed with the SEC to disclose transactions in company stock by corporate insiders. The article provides the title and the date of the filing, along with the company and the individual involved.
Arvinas falls 2.14% in Friday's session
Arvinas shares dropped 2.14% to 6.41 USD in the United States health care sector on November 6, 2026, closing below their previous close of 6.55 USD. This report highlights the stock's performance, noting that its last traded price differs from the exchange's official closing price. The article emphasizes that all financial information is for educational purposes and not investment advice.
Early data on an experimental lymphoma drug will be presented Dec. 14
Arvinas (Nasdaq: ARVN) announced it will present preliminary Phase 1 clinical data for its investigational drug ARV-393 (zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting on December 14, 2026. The presentation will cover safety, pharmacokinetics, and pharmacodynamics from early monotherapy dose-escalation cohorts in patients with relapsed or refractory non-Hodgkin lymphoma, with preliminary efficacy data specifically for T-cell lymphomas. ARV-393 aims to degrade the BCL6 protein, an oncogenic driver in multiple non-Hodgkin lymphomas.
Growth Investors: Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 16%
Analysts have significantly upgraded Arvinas, Inc.'s revenue forecasts for next year by 16%, now expecting US$74m in 2027, although this still represents a substantial decline from the previous year. Concurrently, estimated per-share losses have been reduced. Despite these positive adjustments to sales and loss estimates, analysts have maintained their price target of US$14.46, suggesting that these short-term forecast changes do not alter their long-term valuation of the stock.
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Arvinas, Inc. announced that preliminary clinical data from its Phase 1 study of ARV-393 (zaloblideg), an investigational PROTAC BCL6 degrader, will be presented at the 2026 American Society of Hematology (ASH®) Annual Meeting. The presentation will include safety, pharmacokinetic, and pharmacodynamic data from all patients, alongside preliminary efficacy results from patients with T-cell lymphomas within the relapsed/refractory non-Hodgkin lymphoma (NHL) cohort. ARV-393 is designed to target and degrade the BCL6 protein, a key oncogenic driver in various NHLs.
Arvinas Inc. (ARVN) files $400M mixed shelf
Arvinas Inc. (NASDAQ: ARVN) has filed a mixed shelf offering valued at $400 million. This offering includes various securities such as Debt Securities, Common Stock, Preferred Stock, Depositary Shares, Warrants, and Units.
H.C. Wainwright cuts Arvinas stock price target to $13 from $18
H.C. Wainwright has lowered its price target for Arvinas Inc. (NASDAQ:ARVN) to $13 from $18, while maintaining a Buy rating. The revision follows a reevaluation of launch assumptions and updated development timelines for the company's various assets. Despite being undervalued according to InvestingPro, Arvinas is quickly burning through cash, a common characteristic for clinical-stage biotechs.
Revenue falls to $500K as Arvinas (ARVN) posts a wider Q3 loss.
Arvinas (ARVN) reported third-quarter 2026 revenue of $0.5 million, significantly down from $41.9 million a year earlier, and a net loss that widened to $53.9 million from $35.1 million. The company's cash and marketable securities are expected to fund operations into the second half of 2028, and they have made progress with their PROTAC protein degrader programs, including the FDA approval of VEPPANU. However, the planned Phase 1b trial for ARV-102 in PSP is on clinical hold pending FDA review.
Arvinas Starts ARV-6723 Dosing, Reports $558.9 Million in Liquidity
Arvinas has commenced patient dosing for its ARV-6723 Phase 1/2 trial for advanced solid tumors, with initial data anticipated in the second half of 2027. The company reported $558.9 million in liquidity as of September 30, 2026, which is expected to fund operations into the second half of 2028. Additionally, Arvinas plans to present initial Phase 1 data for ARV-393 at an upcoming hematology meeting in December 2026.
What Arvinas (ARVN) Said on Its Q3 Earnings Call
Arvinas (ARVN) discussed its Q3 2026 earnings, highlighting upcoming clinical milestones in oncology and neurology, reduced operating expenses, and a cash runway extending into mid-2028. The company expects initial data for its BCL6 degrader, ARV-393, at the ASH meeting in December and plans to advance neurology programs ARV-027 for SBMA and ARV-102 for PSP, with patient studies targeted for 2027. Arvinas also initiated a Phase I trial for its immuno-oncology program ARV-6723 and reported its first royalty payment from Rigel.
Up to $200M in potential stock sales is part of Arvinas (ARVN)'s broader offering plan.
Arvinas, Inc. (ARVN) has filed a shelf registration statement indicating it may offer up to $400 million in various securities, including common stock, preferred stock, and debt securities. Within this broader plan, an equity distribution agreement specifically covers the potential sale of up to $200 million in common stock through sales agents. The net proceeds from these offerings are intended for general corporate purposes, such as research and development, potential acquisitions, debt repayment, and working capital.
Arvinas Q3 2026 Earnings Call Transcript
Arvinas reported its Q3 2026 financial results, showcasing $558.9 million in cash and equivalents and a projected cash runway into the second half of 2028. The company is advancing several clinical trials, including ARV393 for lymphoma and ARV027 for spinal bulbar muscular atrophy, with key data readouts anticipated in 2027. Management emphasized data-driven capital allocation and plans to initiate a Phase 1b trial for ARV102 in Europe and the UK for neurodegenerative diseases.
Earnings call transcript: Arvinas Q3 2026 loss narrows, revenue misses sharply
Arvinas (ARVN) reported a narrower-than-expected loss for Q3 2026 but significantly missed revenue forecasts, causing its shares to drop. The biotechnology company posted an adjusted loss of $0.82 per share against an estimated $0.85, but revenue was only $500,000, far below the $16.82 million consensus, primarily from its first royalty under a Rigel license agreement. Despite strong cash reserves ($558.9 million, funding operations into H2 2028) and reduced operating expenses, investors reacted negatively to the substantial revenue miss and limited near-term commercial contributions, sending shares down 4.9% in premarket trading.
Arvinas Submits $400M Shelf Registration Including $200M ATM Equity Offering
Arvinas, Inc. has filed a Form S-3 shelf registration statement with the SEC, allowing for a potential securities offering of up to $400 million. This total includes a specific $200 million at-the-market (ATM) common stock facility. Piper Sandler & Co. and Cantor Fitzgerald & Co. are named as agents for the ATM sales, with the registration pending effectiveness at the time of filing.
Arvinas Q3 2026 Earnings Call Is Live
Arvinas's Q3 2026 earnings call has just started, where executives will discuss financial results and answer questions from analysts. This is an opportunity for those following ARVN to hear management's insights into the company's performance, future demand, margins, and capital spending, which could potentially impact the market.
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its third-quarter 2026 financial results, highlighting significant progress in its clinical-stage protein degrader programs, including the initiation of dosing for ARV-6723 and upcoming clinical data presentations for ARV-393, ARV-027, and ARV-6723. The company reaffirmed its financial guidance, indicating sufficient cash to fund operations into the second half of 2028, despite a decrease in R&D and G&A expenses compared to the previous year.
Arvinas, Inc. (ARVN) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Arvinas, Inc. (ARVN), showing average monthly price returns from 2018 to 2026. It also includes current stock performance, pre-market activity, and details for an upcoming Q3 2026 earnings call. The page experienced an error and primarily displays stock information rather than the full chart.
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company specializing in targeted protein degradation, announced it will report its third-quarter 2026 financial results and provide a corporate update on Tuesday, November 3, 2026, at 8:00 a.m. ET via a live webcast. The company is advancing multiple investigational drugs through clinical development, targeting various diseases including non-Hodgkin Lymphoma, neurodegenerative disorders, spinal-bulbar muscular atrophy, and solid tumors.
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Arvinas, Inc. has announced the return of its Early Career Researcher Award, offering a $25,000 monetary prize to recognize emerging talent in targeted protein degradation (TPD). Nominations will open on November 1, 2026, and close on December 31, 2026, with the winner to be announced in mid-2027. The award aims to foster innovation and creative thinking in the field of TPD, supporting the next generation of scientists.
After Its Vepinu Windfall, Arvinas Must Show A Thinner Pipeline Can Still Deliver
Arvinas, Inc. (ARVN) recently achieved its best quarter due to a one-time Vepinu windfall, but its stock has fallen since, raising concerns about its narrowed clinical pipeline and decreasing cash reserves. With a third-quarter report approaching, the company faces scrutiny over its ability to deliver on remaining pipeline commitments like ARV393 and ARV027, as well as addressing setbacks for ARV806 and ARV102. Investors are looking for strong execution and clear timelines to maintain confidence in Arvinas's long-term strategy rather than viewing the Vepinu approval as a peak achievement.
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Arvinas, Inc. has announced the return of its Early Career Researcher Award, offering a $25,000 prize to recognize emerging researchers or teams innovating in targeted protein degradation (TPD). Nominations will open on November 1, 2026, and close on December 31, 2026, with the winner being announced in mid-2027. The award aims to champion new talent and support scientific advancements in the field of TPD.
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Arvinas, Inc. (Nasdaq: ARVN) announced that it will report its third-quarter 2026 financial results and provide a corporate update on Tuesday, November 3, 2026, at 8:00 a.m. ET. A live webcast of the event will be accessible via the investor page of the company's website, with a replay available afterward. The biotechnology company focuses on developing drugs based on targeted protein degradation.
What Arvinas Holders Got Wrong Before The Slide
Arvinas reported strong Q2 2026 results with significant revenue and net income, a turnaround from previous losses. Despite this, the stock has seen a 36.3% loss year-to-date, prompting a re-evaluation of bullish and bearish narratives for the company. The current share price of US$7.31 suggests a need for buyers to believe in the future clinical success of partnered deals and early programs to justify the valuation.
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company, announced it will report its third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026, at 8:00 a.m. ET. The webcast will be accessible via the "Events and Presentations" section of the company's investor page. Arvinas is focused on developing a new class of drugs based on targeted protein degradation using its PROteolysis TArgeting Chimera (PROTAC) platform.
Arvinas, Inc. Estimates – NASDAQ:ARVN
This article provides access to financial actuals and analyst estimates for Arvinas, Inc. (NASDAQ: ARVN) on TradingView. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also allows visualization of financial trends over time.
Tim Shannon: How a $10 Million Chemistry Bet Turned Protein Degraders Into a $3 Billion Drug
Tim Shannon, co-founder of Arvinas, details how targeted protein degradation evolved from a scientific curiosity into an FDA-approved medicine, leading to a $3 billion acquisition of HALDA Therapeutics by Johnson & Johnson. He emphasizes that a crucial $10 million investment in chemistry to achieve oral bioavailability was pivotal for commercial success. Shannon also discusses the clinical insights gained regarding patient stratification using circulating tumor DNA and his new venture, Quarry, which aims to develop oral antibody mimics for immunology.
Arvinas takes its Parkinson’s degrader to Seoul
Arvinas presented early biomarker data for its Parkinson's drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul. ARV-102 is an oral PROTAC LRRK2 degrader designed to clear disease-causing proteins. The Phase 1 data, from 24 Parkinson's patients, showed improvements in oculomotor function and positive changes in cerebrospinal fluid biomarkers, indicating the drug hit its target and influenced downstream biology.
Arvinas (ARVN) Stock Price, News & Analysis
Arvinas (ARVN) is a clinical-stage biotechnology company focused on developing therapies using its proprietary PROTAC protein degrader platform for oncology and neurodegenerative diseases. Key pipeline programs include vepdegestrant (ARV-471) for breast cancer, ARV-393 for lymphoma, ARV-806 for KRAS G12D-mutated cancers, and ARV-102 for Parkinson's disease. The article also details financial performance, recent news, SEC filings, and upcoming corporate events, providing a comprehensive overview for investors.
Reasons Why Investors Should Consider Betting on Arvinas Stock
Arvinas (ARVN) is presented as an attractive investment due to its clinical-stage biotechnology, validated PROTAC protein degradation technology, and diversified pipeline. The FDA approval of Veppanu, developed in collaboration with Pfizer and out-licensed to Rigel, provides significant validation and potential collaboration revenue. The company's pipeline includes several promising drug candidates for various diseases, with positive early results and upcoming data releases.
Brummer Multi-Strategy AB's Arvinas Inc(ARVN) Holding History
This article details Brummer Multi-Strategy AB's historical holding of Arvinas Inc (ARVN) stock. As of June 30, 2026, Brummer Multi-Strategy AB held no shares of ARVN, having made two purchases and one sale of the stock since late 2025. Based on historical transactions and the current price, their estimated gain on these holdings is a loss of approximately $-625,911.22.
Technical Reactions to ARVN Trends in Macro Strategies
This article analyzes Arvinas Inc. (NASDAQ: ARVN) with a focus on technical reactions to macro strategies. It identifies a mid-channel oscillation pattern and a strong near-term sentiment that could challenge persistent mid and long-term weakness. The report provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
This article details recent analyst ratings for three healthcare companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN), and Ovid Therapeutics (OVID). Bausch Health received a Hold rating from RBC Capital, with Arvinas also getting a Hold rating from Wedbush, though it has a Moderate Buy consensus. Ovid Therapeutics received a Buy rating from Wedbush and holds a Strong Buy consensus among analysts.
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
This article highlights recent analyst ratings for three healthcare companies: Sanofi (SNYNF), Arvinas Holding Company (ARVN), and Halozyme (HALO). Sanofi received a "Moderate Buy" consensus, with Bank of America Securities and J.P. Morgan maintaining "Hold" ratings. Arvinas Holding Company also garnered a "Moderate Buy" consensus, despite Bank of America Securities maintaining a "Hold" rating. Halozyme received a "Strong Buy" consensus, with Leerink Partners reiterating a "Buy" rating.
Arvinas Q3 2026 Earnings Date and Estimates
Arvinas (ARVN) is scheduled to report its Q3 2026 earnings on Wednesday, November 4, 2026, before market open, with a conference call at 8:00 AM ET. Analysts project a loss of -$0.8672 per share on revenues of $16.82 million, a significant decrease from the prior year's revenue of $41.90 million. The company has a strong track record of beating EPS estimates, having done so in 7 of its last 8 quarters.
Arvinas Fell While It Turned A Profit
Arvinas experienced a 35.0% loss for investors year-to-date despite reporting a significant turnaround in Q2 2026, with total revenue of US$249.7 million and net income of US$169.4 million. This shift from a deeply negative to strongly positive net margin, fueled by a substantial increase in revenue, supported an optimistic view for the company. However, the stock price continues to trade below fair value estimates, prompting investors to consider Arvinas's strategic moves in precision medicines, including AI-driven PROTAC design and pipeline developments.
Arvinas Fell While It Turned A Profit
Arvinas (NasdaqGS:ARVN) investors who bought shares at the start of 2026 have experienced a 35% loss, despite the company reporting a significant swing to profitability in Q2 2026. The company's revenue increased substantially, and its net margin turned strongly positive, supporting an optimistic valuation case. However, the current share price of US$7.45 is below the narrative's fair value, suggesting a disconnect between the company's improved financial performance and market perception.
Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55
Arvinas, Inc. (NASDAQ:ARVN) has received an average "Hold" rating from ten analysts, with a consensus 12-month price target of $14.55. The company recently reported strong quarterly earnings, significantly beating estimates with $2.58 EPS and $249.7 million in revenue, a 1,014.7% year-over-year increase. Institutional investors hold approximately 95.2% of the stock.
Arvinas presents phase 1 data for Parkinson’s drug ARV-102
Arvinas Inc. has presented Phase 1 clinical trial data for its investigational Parkinson's drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The trial showed dose-dependent improvements in eye movement (saccadic hypometria) and beneficial changes in biomarkers related to endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance. ARV-102, an orally bioavailable PROTAC degrader, targets LRRK2, which is implicated in neurological diseases like Parkinson's.
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Arvinas Inc. presented novel oculomotor and biomarker data from a Phase 1 clinical trial of ARV-102, a PROTAC degrader for Parkinson’s disease, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The data indicated improvements in impaired eye movement associated with Parkinson’s disease and a correlation between reduced LRRK2 cerebrospinal fluid biomarkers and changes in oculomotor function and synaptic biomarkers. These findings support further clinical evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases linked to LRRK2 dysregulation.
A 28-day study found less severe eye-movement impairment with Arvinas' Parkinson's drug candidate.
Arvinas (Nasdaq: ARVN) presented final Phase 1 data for its investigational drug ARV-102, showing exploratory improvements in eye-movement and positive biomarker changes in Parkinson's disease patients. The 28-day study, involving 24 patients, was not designed for clinical efficacy but indicated dose-dependent reductions in eye-movement impairment and favorable shifts in cellular waste processing and neuroinflammation markers. These findings support further clinical evaluation of ARV-102 as a potential treatment for neurodegenerative diseases linked to LRRK2 dysregulation.
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. announced that novel biomarker data from its Phase 1 clinical trial for ARV-102, an investigational PROTAC LRRK2 degrader for Parkinson's disease, will be presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®. The data will be shared in both oral and poster presentations, detailing oculomotor and biomarker findings. ARV-102 is designed to cross the blood-brain barrier and target LRRK2, a protein implicated in Parkinson's disease and progressive supranuclear palsy.
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of its investigational drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 is a PROTAC LRRK2 degrader designed to treat Parkinson's disease. The data will be shared in both oral and e-poster presentations, detailing oculomotor and biomarker findings from the study.